Related News
Home 禄 Metro 禄 Health and Science
New drug brings relief to orthopedic patients
By Cai Wenjun |
April 16, 2013, Tuesday
|
Online Edition
Online Edition
AN innovative medicine is shown capable of preventing blood clots in the veins of patients who just received hip or knee replacement surgery. The new drug is now available in the Chinese market.
Made by Bristol-Myers Squibb and Pfizer, Eliquis can reduce the risk of venous thromboembolism (VTE) that occurs in some 60 percent of patients with major orthopedic surgeries seven to 14 days later.
VTE is also referred to as deep vein thrombosis if it clots leg veins or pulmonary embolism if it blocks lung arteries, doctors said.
Eliquis has been widely used in the Western countries and its import is a relief for patients in China where about 400,000 hip or knee replacement surgeries are performed each year, doctors said.
Made by Bristol-Myers Squibb and Pfizer, Eliquis can reduce the risk of venous thromboembolism (VTE) that occurs in some 60 percent of patients with major orthopedic surgeries seven to 14 days later.
VTE is also referred to as deep vein thrombosis if it clots leg veins or pulmonary embolism if it blocks lung arteries, doctors said.
Eliquis has been widely used in the Western countries and its import is a relief for patients in China where about 400,000 hip or knee replacement surgeries are performed each year, doctors said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
